Assembly Biosciences Inc (ASMB) Q3 2018 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q3 2018 10-Q quarterly report on Nov 8, 2018 for the quarter ended Sep 30, 2018.

AI summary of MD&A and risk factor updates

Collaboration revenue $4.3M, up $1.6M from $2.7M YoY
R&D expense $16.6M, up $7.2M YoY, driven by HBV-cure spending
Net cash used in operations $48.2M versus $11.6M provided YoY
Financing cash inflow $159.2M, including $155.4M public offering proceeds
Outlook: cash, equivalents and marketable securities funding expected for at least twelve months, additional capital needed thereafter

Newly effective GDPR: compliance became mandatory May 25, 2018, with penalties up to €20 million or 4% of worldwide revenue
Financial loss profile: accumulated deficit approximately $315.6 million at September 30, 2018
Liquidity risk: current resources expected to fund operations for at least the next twelve months
Regulatory approval risk: no BLA or NDA submitted, with candidates remaining in early clinical or nonclinical development
Operational risk: reliance on third-party manufacturers for ABI-H0731, ABI-H2158 and ABI-H3733 trial supplies

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.